- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05020249
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
March 21, 2024 updated by: UCB Biopharma SRL
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
47
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bucheon-si, Korea, Republic of
- Ps0032 20211
-
Busan, Korea, Republic of
- Ps0032 20214
-
Gwangju, Korea, Republic of
- Ps0032 20215
-
Seongnam-si, Korea, Republic of
- Ps0032 20208
-
Seongnam-si, Korea, Republic of
- Ps0032 20210
-
Seoul, Korea, Republic of
- Ps0032 20104
-
Seoul, Korea, Republic of
- Ps0032 20138
-
Seoul, Korea, Republic of
- Ps0032 20213
-
Seoul, Korea, Republic of
- Ps0032 20216
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Study participant must be at least 19 years of age at the time of signing the informed consent
- Study participant must be a Korean adult with a diagnosis of moderate to severe psoriasis (PSO)
- Study participant must have had plaque PSO for at least 6 months prior to the Screening Visit
- Study participant must have Psoriasis Area and Severity Index (PASI) ≥12 and body surface area (BSA) affected by PSO ≥10% and Investigator's Global Assessment (IGA) score ≥3 on a 5-point scale
- Study participant must be a candidate for systemic PSO therapy and/or phototherapy
- Study participant agrees not to change their usual sun exposure during the course of the study and to use ultraviolet A/ultraviolet B sunscreens if unavoidable exposure occurs
- A female study participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:
- Not a female of childbearing potential (FOCBP) OR A FOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 20 weeks after the last dose of study treatment
Exclusion Criteria:
- Subject has an active infection (except common cold), a serious infection, or a history of opportunistic or recurrent chronic infections
- Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency virus (HIV) infection
- Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or has current or history of nontuberculous mycobacterium (NTMB) infection
- Subject has any active malignancy or history of malignancy within 5 years prior to the Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, or in situ cervical cancer
- Study participant has a presence of active suicidal ideation or positive suicide behavior
- Study participant has a presence of moderately severe major depression or severe major depression
- Subject has a known hypersensitivity to any excipients of bimekizumab
- Subject has any other condition, including medical or psychiatric, which, in the Investigator's judgment, would make the subject unsuitable for inclusion in the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bimekizumab arm
Study participants randomized to this arm will receive bimekizumab (BKZ; UCB4940) at pre-specified time points during the Treatment Period.
|
Study participants will receive bimekizumab administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
Other Names:
|
Placebo Comparator: Placebo arm
Study participants randomized to this arm will receive placebo (PBO) at pre-specified time points during the Treatment Period.
|
Study participants will receive placebo administered through subcutaneous injection in a pre-specified sequence during the Treatment Period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16
Time Frame: Week 16
|
The PASI90 response assessments are based on a 90% improvement in the PASI score from Baseline.
This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved.
Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks.
Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked).
Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale.
Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section.
The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
|
Week 16
|
Percentage of Participants With an Investigator's Global Assessment (IGA) 0/1 (Clear or Almost Clear With at Least 2-category Improvement From Baseline) Response at Week 16
Time Frame: Week 16
|
The Investigator's Global Assessment measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= Clear, no signs of psoriasis; post-inflammatory hyperpigmentation may be present, scale 1= Almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= Mild, just detectable to mild thickening, pink to light red coloration and predominately fine scaling, scale 3= Moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and scale 4= Severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.
IGA 0/1 response was defined as clear [0] or almost clear [1] with at least a two-category improvement from Baseline.
|
Week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a Psoriasis Area and Severity Index 100 (PASI100) Response at Week 16
Time Frame: Week 16
|
The PASI100 response assessments are based on a 100% improvement in the PASI score from Baseline.
This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved.
Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks.
Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked).
Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale.
Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section.
The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
|
Week 16
|
Percentage of Participants With an Investigator's Global Assessment (IGA) 0 (Clear With at Least 2-category Improvement From Baseline) Response at Week 16
Time Frame: Week 16
|
The Investigator's Global Assessment measures the overall psoriasis severity following a 5-point scale (0-4), where scale 0= Clear, no signs of psoriasis; post-inflammatory hyperpigmentation may be present, scale 1= Almost clear, no thickening; normal to pink coloration; no to minimal focal scaling, scale 2= Mild, just detectable to mild thickening, pink to light red coloration and predominately fine scaling, scale 3= Moderate, clearly distinguishable to moderate thickening; dull to bright red; moderate scaling and scale 4= Severe, severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions.
IGA 0 response (Clear) is defined as clear [0] with at least a two-category improvement from Baseline.
|
Week 16
|
Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 4
Time Frame: Week 4
|
The PASI75 response assessments are based on at least 75% improvement in the PASI score from Baseline.
This is a scoring system that averages the redness, thickness, and scaliness of the psoriatic lesions (on a 0-4 scale), and weights the resulting score by the area of skin involved.
Body divided into 4 areas: head, arms, trunk to groin, and legs to top of buttocks.
Assignment of an average score for the redness, thickness, and scaling for each of the 4 body areas with a score of 0 (clear) to 4 (very marked).
Determining the percentage of skin covered with PSO for each of the body areas and converting to a 0 to 6 scale.
Final PASI= average redness, thickness, and scaliness of the psoriatic skin lesions, multiplied by the involved psoriasis area score of the respective section, and weighted by the percentage of the person's affected skin for the respective section.
The minimum possible PASI score is 0= no disease, the maximum score is 72= maximal disease.
|
Week 4
|
Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Itch at Week 16
Time Frame: Week 16
|
The PSD (P-SIM) was designed for use as a daily diary to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours, on a 0-10 point numeric rating scale (NRS) where 0 (no symptoms/impact) and 10 (very severe symptoms/worst impact).
It consists of 14 items measuring: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment and choice of clothing.
A weekly score for each item (including itch) is obtained as an average of daily values for the considered item over the 7 days preceding the visit (weekly score range: 0 (no itch)-10 (very severe itch)).
Itch response was defined as a reduction from baseline to Week 16 of at least 4 points on the PSD itch weekly score.
|
Week 16
|
Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Pain at Week 16
Time Frame: Week 16
|
The PSD (P-SIM) was designed for use as a daily diary to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours, on a 0-10 point NRS where 0 (no symptoms/impact) and 10 (very severe symptoms/worst impact).
It consists of 14 items measuring: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment and choice of clothing.
A weekly score for each item (including pain) is obtained as an average of daily values for the considered item over the 7 days preceding the visit (weekly score range: 0 (no pain)-10 (very severe pain)).
Pain response was defined as a reduction from baseline to Week 16 of at least 4 points on the PSD pain weekly score.
|
Week 16
|
Percentage of Participants With a Patient Symptom Diary (PSD) (P-SIM) Response for Scaling at Week 16
Time Frame: Week 16
|
The PSD (P-SIM) was designed for use as a daily diary to collect data about the experience of participants with moderate to severe psoriasis related to the severity of signs, symptoms or impacts, at their worst during the past 24 hours, on a 0-10 point numeric rating scale (NRS) where 0 (no symptoms/impact) and 10 (very severe symptoms/worst impact).
It consists of 14 items measuring: redness, scaling, cracking, lesions, thickening, itch, pain, burning, dryness, irritation, sensitivity, fatigue, embarrassment and choice of clothing.
A weekly score for each item (including scaling) is obtained as an average of daily values for the considered item over the 7 days preceding the visit (weekly score range: 0 (no scaling)-10 (very severe scaling)).
Scaling response was defined as a reduction from baseline to Week 16 of at least 4 points on the PSD scaling weekly score.
|
Week 16
|
Percentage of Participants With Scalp IGA Response 0/1 (Clear or Almost Clear With at Least a 2-category Improvement From Baseline) at Week 16 for Study Participants With Scalp Psoriasis (PSO) at Baseline
Time Frame: Week 16
|
Participants with scalp involvement at Baseline were defined as those with a scalp IGA score >0 at Baseline.
Scalp lesions were assessed in terms of clinical signs of redness, thickness, and scaliness using a 5-point scale (0=Clear, 1=Almost Clear, 2=Mild, 3=Moderate, 4= Severe).
Scalp IGA response 0/1 at Week 16 was defined as clear (0) or almost clear (1) with at least a 2-category improvement from Baseline to Week 16.
|
Week 16
|
Percentage of Participants With Dermatology Life Quality Index (DLQI) 0/1 Response at Week 16
Time Frame: Week 16
|
The DLQI is a skin disease-specific questionnaire aimed at the evaluation of how symptoms and treatment affect study participants' health related quality of life (QOL).
This instrument asks study participants about symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment.
It has been shown to be valid and reproducible in study participants with PSO.
The DLQI total score ranges from 0 to 30, with higher scores indicating lower health related QOL.
A 4-point change in the DLQI total score has been reported to be meaningful for the study participant (within-participant minimal important difference); while a DLQI total score of 0 or 1 indicates no impact of the skin disease on participant's life.
|
Week 16
|
Percent Change From Baseline in Body Surface Area (BSA) Affected by PSO at Week 16
Time Frame: Baseline, Week 16
|
The Total BSA affected by PSO was entered as a percentage from 0 to 100.
|
Baseline, Week 16
|
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study
Time Frame: From Baseline to End of Safety Follow-Up (SFU) (up to Week 32)
|
An adverse event is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
TEAEs were defined as those AEs that have a start date on or following the first dose of investigational medicinal product (IMP) through the end of the time at risk.
|
From Baseline to End of Safety Follow-Up (SFU) (up to Week 32)
|
Percentage of Participants With Treatment-emergent Serious Adverse Events (TESAEs) Throughout the Study
Time Frame: From Baseline to End of Safety Follow-Up (up to Week 32)
|
A serious adverse event (SAE) is any untoward medical occurrence that at any dose: 1) Results in death 2) Is life-threatening 3) Requires in participant hospitalisation or prolongation of existing hospitalisation 4) Resulted in persistent disability/incapacity 5) Is a congenital anomaly or birth defect 6) Other important medical events which based on medical or scientific judgement may jeopardise the participants, or may require medical or surgical intervention to prevent any of the above.
|
From Baseline to End of Safety Follow-Up (up to Week 32)
|
Percentage of Participants With TEAEs Leading to Permanent Discontinuation of Investigational Medicinal Product (IMP) Throughout the Study
Time Frame: From Baseline to End of Safety Follow-Up (up to Week 32)
|
An adverse event is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of IMP, whether or not considered related to the IMP.
An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.
TEAEs were defined as those AEs that have a start date on or following the first dose of IMP through the end of the time at risk.
|
From Baseline to End of Safety Follow-Up (up to Week 32)
|
Change From Baseline in Patient Health Questionnaire 9 (PHQ-9) at Week 16
Time Frame: Baseline, Week 16
|
The PHQ-9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring the severity of depression.
The PHQ-9 score ranges from 0 to 27 with higher scores indicating a worse state.
A score of 5 to 9 is considered to be minimal symptoms of depression.
A score of 10 to 14 is considered minor depression, dysthymia, or mild major depression.
A score of 15 to 19 is considered to indicate moderately severe major depression, and a score ≥20 is considered to be severe major depression.
Change from Baseline is derived as post-Baseline score minus Baseline score, where a positive change indicates worsening and a negative change indicates improvement.
|
Baseline, Week 16
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: UCB Cares, 001 844 599 2273
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 27, 2021
Primary Completion (Actual)
September 5, 2022
Study Completion (Actual)
September 6, 2022
Study Registration Dates
First Submitted
August 20, 2021
First Submitted That Met QC Criteria
August 20, 2021
First Posted (Actual)
August 25, 2021
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 21, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PS0032
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion.
Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report.
Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org
and a signed data sharing agreement will need to be executed.
All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal.
This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
IPD Sharing Time Frame
Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD Sharing Access Criteria
Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report.
Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org
and a signed data sharing agreement will need to be executed.
All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Moderate to Severe Plaque Psoriasis
-
Idera Pharmaceuticals, Inc.CompletedModerate to Severe Plaque Psoriasis | Actively Extending Plaque PsoriasisUnited States
-
Fresenius Kabi SwissBioSim GmbHMerck KGaA, Darmstadt, GermanyCompletedPsoriasis | Moderate to Severe Plaque Psoriasis | Plaque Type PsoriasisUnited States, Canada, Czechia, Hungary, Russian Federation, Bulgaria, Mexico, United Kingdom, Poland, Germany, Estonia, France
-
UCB Biopharma SRLCompletedModerate to Severe Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Canada
-
Bristol-Myers SquibbNot yet recruitingModerate-to-severe Plaque PsoriasisKorea, Republic of
-
Novartis PharmaceuticalsRecruitingModerate-to-severe Plaque PsoriasisRussian Federation
-
Novartis PharmaceuticalsCompletedModerate-to-severe Plaque PsoriasisIndonesia
-
AbbVie (prior sponsor, Abbott)CompletedModerate to Severe Plaque PsoriasisGermany
-
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...UnknownModerate to Severe Plaque PsoriasisChina
-
Bausch Health Americas, Inc.TerminatedModerate to Severe Plaque PsoriasisUnited States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Clinical Trials on bimekizumab
-
UCB Biopharma SRLCompletedModerate to Severe Chronic Plaque Psoriasis | Chronic Plaque PsoriasisUnited States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
-
UCB Biopharma SRLCompletedPsoriatic ArthritisUnited States, Czechia, Germany, Hungary, Poland, Russian Federation
-
UCB Biopharma S.P.R.L.CompletedHealthy VolunteersUnited States, Germany
-
UCB Biopharma SRLCompletedAnkylosing SpondylitisUnited States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine
-
UCB Biopharma SRLCompletedChronic Plaque PsoriasisUnited States, Australia, Canada, Moldova, Republic of
-
UCB Biopharma SRLCompletedHidradenitis SuppurativaUnited States, Australia, Bulgaria, Canada, Czechia, France, Germany, Hungary, Ireland, Israel, Japan, Poland, Spain, United Kingdom
-
UCB Biopharma SRLActive, not recruitingHidradenitis SuppurativaUnited States, Australia, Belgium, Bulgaria, Canada, Czechia, France, Germany, Greece, Hungary, Ireland, Italy, Japan, Netherlands, Poland, Spain, Switzerland, Turkey, United Kingdom
-
UCB Biopharma SRLActive, not recruitingAnkylosing Spondylitis | Axial Spondyloarthritis | r-axSpa | Nr-axSpaUnited States, Belgium, Bulgaria, China, Czechia, France, Germany, Hungary, Japan, Netherlands, Poland, Spain, Turkey, United Kingdom
-
UCB Biopharma S.P.R.L.CompletedPsoriatic ArthritisUnited States, Czechia, Germany, Hungary, Poland, Russian Federation
-
UCB Biopharma SRLTerminatedHealthy Study ParticipantsGermany